8-K: Aprea Therapeutics Announces Positive First Quarter Results and Clinical Trial Progress

Aprea Therapeutics reported its first quarter 2024 financial results, highlighted by FDA clearance for APR-1051 and progress in the ATRN-119 clinical trial.

Summary

• Aprea Therapeutics announced its financial results for the first quarter of 2024, ending March 31, 2024.
• The company reported cash and cash equivalents of $32.4 million, up from $21.6 million at the end of 2023.
• Aprea believes its current cash will fund operations into the third quarter of 2025.
• The company's operating loss for the quarter was $3.1 million, an improvement from $4.6 million in the same period last year.
• Research and Development expenses increased to $1.6 million, up from $1.3 million in the first quarter of 2023, primarily due to IND enabling studies for APR-1051.
• General and Administrative expenses decreased to $1.9 million, down from $3.4 million in the same period last year, mainly due to reduced personnel costs.
• The net loss for the quarter was $2.8 million, or $0.67 per basic share, compared to a net loss of $4.4 million, or $1.34 per basic share, in the first quarter of 2023.
• The company received FDA clearance for its Investigational New Drug (IND) application for APR-1051, a WEE1 inhibitor.
• Aprea plans to initiate a Phase 1 clinical trial for APR-1051 in June 2024.
• The company's ATR inhibitor, ATRN-119, is on track to complete dose escalation in its clinical trial, with potential initial efficacy data expected in the second half of 2024.
• Aprea raised $16 million in gross proceeds through a private placement in March 2024, with the potential for an additional $18 million upon exercise of warrants.
• Nadeem Q. Mirza, M.D., M.P.H., was appointed as Chief Medical Officer, effective May 1, 2024.

Sentiment

Score: 8

Explanation: The document presents a positive outlook with significant clinical and financial progress. The company has achieved key milestones, secured funding, and is advancing its pipeline. There are some risks, but the overall tone is optimistic.

Positives

• The company has a strong cash position of $32.4 million, which is expected to fund operations into the third quarter of 2025.
• The FDA clearance of the IND for APR-1051 is a significant regulatory milestone.
• The company is making good progress with its clinical trials for both ATRN-119 and APR-1051.
• The private placement in March 2024 provides additional capital to fund clinical programs.
• The appointment of a new Chief Medical Officer strengthens the leadership team.
• The company's operating loss has decreased compared to the same period last year.
• Preclinical data for APR-1051 shows it is a potent and selective WEE1 inhibitor with minimal off-target effects.
• ATRN-119 is a first-in-class macrocyclic ATR inhibitor with a differentiated structure and toxicity profile.

Negatives

• The company is still operating at a loss, with a net loss of $2.8 million for the quarter.
• Research and development expenses have increased, which is expected for a clinical-stage company but still represents a cash outflow.
• The company is dependent on additional financing to fund its operations and complete the development and commercialization of its product candidates.

Risks

• The success and timing of clinical trials are subject to risks and uncertainties.
• The company's ability to raise additional capital may restrict operations or require relinquishing rights to technologies or product candidates.
• There are risks associated with the interpretation of preclinical and early clinical results.
• The company faces competition from other companies developing similar therapies.
• The company's forward-looking statements are subject to risks and uncertainties that could cause actual results to differ materially.

Future Outlook

Aprea believes its current cash and cash equivalents will be sufficient to meet its operating expenses and capital expenditure requirements into the third quarter of 2025. The company anticipates several clinical milestones in the coming quarters, including the initiation of the Phase 1 trial for APR-1051 and the completion of dose escalation for ATRN-119.

Management Comments

• Oren Gilad, Ph.D., President and Chief Executive Officer of Aprea, stated that the FDA clearance of the IND for APR-1051 was an important milestone.
• He also mentioned that the company has a strong balance sheet and the recent private placement provides capital to fund lead programs through meaningful clinical milestones.
• Management believes that strategic initiatives and pipeline expansion have the potential to drive substantial value for shareholders.

Industry Context

Aprea is operating in the competitive field of precision oncology, focusing on synthetic lethality. The company's approach of targeting DDR pathways with ATR and WEE1 inhibitors aligns with current trends in cancer drug development. The company is competing with other companies developing similar therapies, such as AstraZeneca and Zentalis, but is attempting to differentiate itself with its macrocyclic ATR inhibitor and highly selective WEE1 inhibitor.

Comparison to Industry Standards

• Aprea's ATRN-119 is a macrocyclic ATR inhibitor, which is a unique approach compared to first-generation acyclic ATR inhibitors like AstraZeneca's AZD6738 and Bayer's BAY1895344, which have shown hematological toxicities and require intermittent dosing.
• Aprea's APR-1051 is designed to be more selective for WEE1 and have less off-target effects than other WEE1 inhibitors like AstraZeneca's Adavosertib (AZD-1775) and Zentalis' Azenosertib (ZN-c3), which have shown significant Grade 3 toxicities.
• The company's focus on continuous dosing for ATRN-119 is a potential advantage over intermittent dosing schedules used by competitors, which may lead to tumor resistance.
• The company's preclinical data for APR-1051 shows a favorable PK profile compared to other WEE1 inhibitors, with higher Cmax and AUC values at similar doses.

Management Changes

Stakeholder Impact

• Shareholders: The company's progress and financial stability are positive for shareholders, with potential for future value creation.
• Employees: The company's growth and clinical advancements may provide job security and opportunities for career development.
• Patients: The development of new cancer therapies could provide hope and new treatment options for patients with unmet medical needs.
• Investors: The company's financial position and clinical progress may attract further investment.
• Creditors: The company's financial stability and cash position reduce the risk for creditors.

Next Steps

• Initiate the Phase 1 ACESOT-1051 clinical trial for APR-1051 in June 2024.
• Complete dose escalation for ATRN-119 in the ABOYA-119 clinical trial.
• Announce initial efficacy data from Part 1 of the ABOYA-119 trial in the second half of 2024.
• Determine the recommended Phase 2 dose (RP2D) for ATRN-119 in the first quarter of 2025.
• Begin enrollment in the Phase 2a cohort of the ATRN-119 trial in the first quarter of 2025.
• Select a lead molecule for a third synthetic lethality program in the third quarter of 2024.

Key Dates

Keywords

Aprea Therapeutics, Precision Oncology, Synthetic Lethality, ATRN-119, APR-1051, ATR inhibitor, WEE1 inhibitor, Clinical Trial, FDA clearance, DDR, Oncology, Biopharmaceutical